Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
WARREN N.J., Jan. 06, 2017 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced the completion of a dose proportionality study evaluating Diazepam Buccal Soluble Film (Diazepam BSF) for the treatment of Acute Repetitive Seizures (ARS).
Diazepam BSF, based on MonoSol Rx’s proprietary and patented PharmFilm technology, is a benzodiazepine used to treat ARS, as well as a variety of other indications including anxiety disorders, alcohol withdrawal symptoms, muscle spasms and seizures. The only product currently indicated for ARS is Diastat Rectal Gel. MonoSol Rx’s Diazepam BSF could potentially be the first and only oral treatment available for ARS sufferers.
The results show that MonoSol Rx’s Diazepam BSF is linear across all dosage strengths. This compares favorably to publicly available data for other alternative diazepam dosage forms. Based on this comparison, MonoSol Rx plans to initiate a pivotal study of Diazepam BSF in adults with ARS in the first quarter of 2017.
“We are extremely excited by the results of this study, which demonstrate that the pharmacokinetic profile of Diazepam BSF is consistent across dose strengths,” said Keith Kendall, CEO of MonoSol Rx. “We believe that Diazepam BSF will be able to overcome the many challenges associated with alternate delivery methods of this molecule and offers the potential to improve outcomes for ARS patients in need. We look forward to the continued progress of our Diazepam BSF program in the coming months.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, convenience, compliance and pharmacoeconomics of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
